- Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023
- Raised $68.3 million in gross proceeds from a concurrent public offering and private placement
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended March 31, 2023 and provided a business update.
“In the first quarter we achieved a key milestone with the completion of enrollment of the pivotal STRIDE study. We have been encouraged by the patient interest in our mavodelpar program, which led to an over-enrollment in STRIDE and high rate of rollover into the STRIDE AHEAD open-label long-term extension trial,” said Gregory J. Flesher, President and Chief Executive Officer of Reneo Pharmaceuticals. “Subsequent to achieving this milestone, we raised additional capital to strengthen our balance sheet. We expect that this capital will be utilized to support the mavodelpar program through completion and in preparation for commercialization activities, including the potential filing of a new drug application in the first half of 2024.”
First Quarter and Recent Highlights
- Completed enrollment with 213 patients in the pivotal STRIDE study of mavodelpar (REN001) in adult patients with primary mitochondrial myopathies (PMM), exceeding the target enrollment of 200 patients; topline results anticipated in the fourth quarter of 2023
- Enrolled over 100 patients in the STRIDE AHEAD study, the mavodelpar open-label extension (OLE) trial in adult patients with PMM; over 50 patients reaching 6-months in the study
- The STRIDE AHEAD study was amended to allow the enrollment of adult patients with PMM due to nuclear DNA (nDNA) defects; initiate enrollment of nDNA patients in the second quarter of 2023
- Received Fast Track Designation from the United States (US) Food and Drug Administration (FDA) for mavodelpar in a genotype of long-chain fatty acid oxidation disorder (LC-FAOD)
- Presented preclinical poster at Society for Inherited Metabolic Disorders (SIMD) Annual Meeting entitled, PPARδ Agonist REN001 Improves Mitochondrial Function in Skeletal Muscle: A Potential Treatment for Primary Mitochondrial Myopathies
- Raised $68.3 million in gross proceeds from a concurrent public offering and private placement in May 2023
Financial Results for the Three Months Ended March 31, 2023
We reported a net loss of $15.1 million, or $0.60 per share, during the first quarter of 2023, compared to a net loss of $13.0 million, or $0.53 per share, for the same period in 2022. We had $93.8 million in cash, cash equivalents, and short-term investments as of March 31, 2023.
Research and development (R&D) expenses were $11.0 million during the first quarter of 2023, compared to $9.3 million for the same period in 2022. This increase in R&D expenses was primarily due to an increase of $1.4 million related to clinical study costs in support of marketing registration of mavodelpar.
General and administrative (G&A) expenses were $5.1 million during the first quarter of 2023, compared to $3.7 million for the same period in 2022. This increase in G&A expenses was primarily due to an increase of $1.1 million in facility and personnel-related costs due to additional headcount.
On May 8, 2023, we completed a public offering in which we sold an aggregate of 7,906,250 shares of common stock, which included the full exercise of the underwriters’ option to purchase an additional 1,031,250 shares of common stock, at a price of $8.00 per share. We received total net proceeds from the offering of approximately $58.2 million, after deducting underwriting discounts and commissions and offering expenses.
On May 9, 2023, we completed a concurrent private placement in which we sold an aggregate of 625,000 shares of common stock to Abingworth Bioventures 8 L.P., a holder of more than 5% of our common stock, at a price of $8.00 per share. We received total net proceeds from the private placement of approximately $4.7 million, after deducting advisor fees and other estimated fees and expenses.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Mavodelpar (REN001) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: PMM and LC-FAOD. For additional information, please see clinicaltrials.gov.
PMM are a group of rare, genetic metabolic disorders caused by mutations or deletions in the mtDNA or nDNA. These genetic alterations hamper the ability of mitochondria to generate energy from nutrient sources, resulting in energy deficits that are most pronounced in tissues with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness, exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential development, registration and commercialization of mavodelpar, results, conduct, progress, plans and timing of Reneo’s clinical trials, timing for the filing of a new drug application and for the first patient enrolled in the STRIDE AHEAD study, announcement of topline data from the STRIDE study and the use of the proceeds from our recent public offering and private placement. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
RENEO PHARMACEUTICALS, INC.
Consolidated Balance Sheets
(In thousands, except share and par value data)
|Cash and cash equivalents||$||30,395||$||19,927|
|Prepaid expenses and other current assets||3,231||5,180|
|Total current assets||97,018||106,353|
|Property and equipment, net||581||453|
|Other non-current assets||81||84|
|Liabilities and stockholders’ equity|
|Operating lease liabilities, current portion||363||404|
|Total current liabilities||10,481||7,124|
|Operating lease liabilities, less current portion||979||1,059|
|Commitments and contingencies|
|Common stock, $0.0001 par value; 200,000,000 shares authorized at|
March 31, 2023 and December 31, 2022; 25,107,430 and 24,699,553 shares
issued and outstanding at March 31, 2023 and December 31, 2022,
|Additional paid-in capital||238,859||236,693|
|Accumulated other comprehensive income (loss)||12||(43||)|
|Total stockholders’ equity||87,084||99,970|
|Total liabilities and stockholders’ equity||$||98,868||$||108,182|
RENEO PHARMACEUTICALS, INC.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
|Three Months Ended March 31,|
|Research and development||$||10,991||$||9,278|
|General and administrative||5,132||3,737|
|Total operating expenses||16,123||13,015|
|Loss from operations||(16,123||)||(13,015||)|
|Other income (loss)||1,016||(21||)|
|Unrealized gain on short-term investments||55||30|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.60||)||$||(0.53||)|
|Weighted-average shares used in computing net loss per share, basic and diluted||25,036,410||24,458,290|
RENEO PHARMACEUTICALS, INC.
Consolidated Statements of Cash Flows
|Three Months Ended|
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||41||19|
|Amortization/accretion on short-term investments||(770||)||1|
|Changes in the fair value of performance award||295||(387||)|
|Non-cash lease expense||120||143|
|Loss on disposal of fixed asset||3||—|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||1,952||2,011|
|Accounts payable and accrued expenses||3,398||1,251|
|Operating lease liabilities||(137||)||(108||)|
|Net cash used in operating activities||(9,048||)||(8,999||)|
|Cash flows from investing activities|
|Purchases of property and equipment||(172||)||(44||)|
|Purchase of available-for-sale short-term investments||(28,321||)||(16,029||)|
|Proceeds from maturities of available-for-sale short-term investments||47,000||21,500|
|Net cash provided by investing activities||18,507||5,427|
|Cash flows from financing activities|
|Proceeds from at-the-market facility, net of offering costs||1,009||6|
|Net cash provided by financing activities||1,009||6|
|Net increase (decrease) in cash and cash equivalents||10,468||(3,566||)|
|Cash and cash equivalents, beginning of period||19,927||124,660|
|Cash and cash equivalents, end of period||$||30,395||$||121,094|
|Noncash operating activities:|
|Right-of-use assets obtained in exchange for lease obligations||$||—||$||1,524|
Reneo Pharmaceuticals, Inc.
David Melamed, Ph.D.
Russo Partners, LLC
Source: Reneo Pharmaceuticals, Inc.